Market Research Logo

Hyperuricemia - Pipeline Review, H2 2015

Hyperuricemia - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Hyperuricemia - Pipeline Review, H2 2015’, provides an overview of the Hyperuricemia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hyperuricemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperuricemia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hyperuricemia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Hyperuricemia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Hyperuricemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Hyperuricemia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Hyperuricemia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Hyperuricemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Hyperuricemia Overview
Therapeutics Development
Pipeline Products for Hyperuricemia - Overview
Pipeline Products for Hyperuricemia - Comparative Analysis
Hyperuricemia - Therapeutics under Development by Companies
Hyperuricemia - Therapeutics under Investigation by Universities/Institutes
Hyperuricemia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Hyperuricemia - Products under Development by Companies
Hyperuricemia - Products under Investigation by Universities/Institutes
Hyperuricemia - Companies Involved in Therapeutics Development
AstraZeneca Plc
CymaBay Therapeutics, Inc.
Kissei Pharmaceutical Co., Ltd.
LG Life Science LTD.
Nippon Chemiphar Co., Ltd.
Polaris Pharmaceuticals, Inc.
Selecta Biosciences, Inc.
Takeda Pharmaceutical Company Limited
Teijin Limited
Hyperuricemia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles arhalofenate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
febuxostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
febuxostat XR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JPH-367 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KGO-2142 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KGO-2173 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LC-350189 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NC-2500 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegadricase - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegadricase - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RDEA-3170 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit Xanthine Oxidase for Hyperuricemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XEN-102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hyperuricemia - Recent Pipeline Updates
Hyperuricemia - Dormant Projects
Hyperuricemia - Discontinued Products
Hyperuricemia - Product Development Milestones
Featured News & Press Releases
Nov 05, 2015: CymaBay Therapeutics to Present Results From Two Arhalofenate Phase 2 Studies at the American College of Rheumatology Annual Meeting, November 6 - 11
Jun 30, 2015: New Indication for Teijin Pharma’s Febuxostat in Europe
Jan 12, 2015: Cymabay Therapeutics Announces Positive Results From Its Phase 2 Clinical Study of Arhalofenate in Combination With Febuxostat
Nov 01, 2013: Mylan Confirms First-to-File Patent Challenge Relating to Uloric
Apr 11, 2012: Teijin Pharma And Menarini Sign Distribution Agreement For Marketing Of Febuxostat
Dec 08, 2011: Metabolex Announces Positive Results From Clinical Study Of Arhalofenate In Combination With Febuxostat
Jul 28, 2011: Teijin Pharma Launches Febuxostat In Korea
May 13, 2011: Teijin Pharma To Launch FEBURIC In Japan
Apr 18, 2011: Teijin Pharma Expands Global Market For TMX-67
Jan 21, 2011: Teijin Pharma Receives Approval Of TMX-67 For Treating Hyperuricemia In Japan
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Hyperuricemia, H2 2015
Number of Products under Development for Hyperuricemia - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Hyperuricemia - Pipeline by AstraZeneca Plc, H2 2015
Hyperuricemia - Pipeline by CymaBay Therapeutics, Inc., H2 2015
Hyperuricemia - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2015
Hyperuricemia - Pipeline by LG Life Science LTD., H2 2015
Hyperuricemia - Pipeline by Nippon Chemiphar Co., Ltd., H2 2015
Hyperuricemia - Pipeline by Polaris Pharmaceuticals, Inc., H2 2015
Hyperuricemia - Pipeline by Selecta Biosciences, Inc., H2 2015
Hyperuricemia - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015
Hyperuricemia - Pipeline by Teijin Limited, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Hyperuricemia Therapeutics - Recent Pipeline Updates, H2 2015
Hyperuricemia - Dormant Projects, H2 2015
Hyperuricemia - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Hyperuricemia, H2 2015
Number of Products under Development for Hyperuricemia - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Targets, H2 2015
Number of Products by Stage and Targets, H2 2015
Number of Products by Mechanism of Actions, H2 2015
Number of Products by Stage and Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report